Flux Power Holdings Inc vs Nuvalent Inc — how do they compare? Flux Power Holdings Inc trades at $0.7 (market cap $15.37M), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Nuvalent Inc is far larger — about 638.3× Flux Power Holdings Inc's market cap, and Nuvalent Inc is trading nearer its 52-week high, Flux Power Holdings Inc nearer its low. Which is the better fit depends on your goals.
| FLUX | NUVL | |
|---|---|---|
Market Cap | $15.37M | $9.81B |
Sector | Utilities | Technology |
52-Week High | $6.66 | $123.96 |
52-Week Low | $0.71 | $72.16 |
Enterprise Value | $21.53M | $8.52B |
Signals from Pluang's Aura AI — not financial advice
FLUX trades at $0.701, down 2.18% today, with a bearish technical signal from moving averages. The company reported a net loss of $6.67M in 2025 with revenue of $66.43M, though the price-to-sales ratio remains low at 0.27. Recent news highlights the launch of SkyEMS 3.0 AI software and new executive hires aimed at growth. Analysts are unanimously bullish with 6 buy ratings, contrasting with negative profitability metrics like a -52.27% ROE.
The outlook hinges on execution of growth initiatives amid persistent losses. Opportunities include market expansion in clean energy and software, while risks involve cash flow volatility and competitive pressures. Investors should weigh analyst optimism against fundamental challenges in the evolving energy storage sector.
Nuvalent (NUVL) trades at $123.96, unchanged on the day, amid a pending $124 per share acquisition by GSK. The stock shows a bullish technical signal with moving averages supporting upside, though RSI levels suggest overbought conditions. Fundamentally, the company remains unprofitable with negative ROE and ROA, while cash flow is sustained by financing activities. Recent news is dominated by merger investigations and strategic rationale for the GSK deal.
The investment outlook hinges on the acquisition closing at $124, offering limited upside from current levels. Risks include shareholder litigation and regulatory scrutiny, but the deal provides a clear exit amid ongoing losses. Analyst sentiment is mixed with a slight hold bias, reflecting uncertainty around deal completion and fairness.
Trailing returns across standard periods
Latest headlines on both assets
Flux Power designs and manufactures lithium-ion battery packs for industrial vehicles. Its sustainable energy solutions power material handling equipment like forklifts and airport ground support vehicles.
Read more on FLUX →Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →